Avacta Group (AIM:AVCT) - Aktienkurs, Nachrichten und Analyse

AVCT Aktienübersicht

Avacta Group Plc entwickelt Krebsmedikamente und In-vitro-Diagnostika im Vereinigten Königreich, in Frankreich, Nordamerika, Südkorea, im übrigen Europa und auf internationaler Ebene.

Über das Unternehmen

AVCT grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	1/6
Künftiges Wachstum	1/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	3/6
Dividenden	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 10.82%

Risikoanalyse

Stark schwankender Aktienkurs in den letzten 3 Monaten

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 3.5% pro Jahr sinken.

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Die Aktionäre wurden im vergangenen Jahr verwässert

Avacta Group Plc Wettbewerber

Bioventix

AIM:BVXP

UK£206.2m

Oxford Biomedica

LSE:OXB

UK£389.8m

Arecor Therapeutics

AIM:AREC

UK£25.5m

Tissue Regenix Group

AIM:TRX

UK£40.2m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Avacta Group
Historische Aktienkurse
Aktueller Aktienkurs	UK£0.51
52-Wochen-Hoch	UK£1.67
52-Wochen-Tief	UK£0.40
Beta	1.12
11 Monat Veränderung	-33.11%
3 Monate Veränderung	-2.88%
1 Jahr Veränderung	-58.78%
33 Jahre Veränderung	-57.42%
5 Jahre Veränderung	149.38%
Veränderung seit IPO	-87.22%

Aktuelle Nachrichten und Updates

Avacta Group Plc's (LON:AVCT) 29% Share Price Surge Not Quite Adding Up

Sep 05

Improved Revenues Required Before Avacta Group Plc (LON:AVCT) Shares Find Their Feet

Jun 21

Recent updates

Avacta Group Plc's (LON:AVCT) 29% Share Price Surge Not Quite Adding Up

Sep 05

Improved Revenues Required Before Avacta Group Plc (LON:AVCT) Shares Find Their Feet

Jun 21

This Is The Reason Why We Think Avacta Group Plc's (LON:AVCT) CEO Deserves A Bump Up To Their Compensation

Jun 22

Avacta Group (LON:AVCT) Is In A Good Position To Deliver On Growth Plans

Jun 20

Avacta Group Plc (LON:AVCT) Insiders Have Been Selling

Feb 18

Companies Like Avacta Group (LON:AVCT) Are In A Position To Invest In Growth

Jan 23

What Kind Of Shareholders Hold The Majority In Avacta Group Plc's (LON:AVCT) Shares?

Dec 27

How Is Avacta Group's (LON:AVCT) CEO Paid Relative To Peers?

Dec 06

Aktionärsrenditen

	AVCT	GB Biotechs	GB Markt
7D	-21.7%	0.8%	0.03%
1Y	-58.8%	-19.1%	7.4%

Rendite im Vergleich zur Industrie: AVCT unter dem Niveau der Branche UK Biotechs , die im vergangenen Jahr eine Rendite von -18.4% erzielte.

Rendite vs. Markt: AVCT hinter dem Markt UK zurück, der im vergangenen Jahr eine Rendite von 11.8 erzielte.

Preisvolatilität

Is AVCT's price volatile compared to industry and market?
AVCT volatility
AVCT Average Weekly Movement	12.4%
Biotechs Industry Average Movement	7.0%
Market Average Movement	4.6%
10% most volatile stocks in GB Market	9.3%
10% least volatile stocks in GB Market	2.6%

Stabiler Aktienkurs: AVCTDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: AVCTDie wöchentliche Volatilität (12%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der UK Aktien.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2003	154	Chris Coughlin	www.avacta.com

Avacta Group Plc entwickelt Krebsmedikamente und In-vitro-Diagnostika im Vereinigten Königreich, Frankreich, Nordamerika, Südkorea, im übrigen Europa und international. Das Unternehmen ist in den Segmenten Diagnostika und Therapeutika tätig. Es bietet seine proprietären Affimer- und pre|CISION-Technologieplattformen an, die zur Bereitstellung eines Portfolios differenzierter therapeutischer und diagnostischer Produkte für verschiedene Märkte verwendet werden.

Avacta Group Plc's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Avacta Group im Vergleich zum Marktanteil des Unternehmens?
AVCT grundlegende Statistiken
Marktanteil	UK£181.17m
Gewinn(TTM)	-UK£24.95m
Umsatz(TTM)	UK£23.25m

7.8x

Kurs-Umsatz-Verhältnis

-7.3x

Kurs-Gewinn-Verhältnis

Ist AVCT zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
AVCT Gewinn- und Verlustrechnung (TTM)
Einnahmen	UK£23.25m
Kosten der Einnahmen	UK£12.00m
Bruttogewinn	UK£11.24m
Sonstige Ausgaben	UK£36.19m
Umsatz	-UK£24.95m

Zuletzt gemeldete Gewinne

Dec 31, 2023

Datum des nächsten Gewinnberichts

Sep 30, 2024

Gewinn per Aktie (EPS)	-0.07
Bruttomarge	48.37%
Nettogewinnspanne	-107.31%
Schulden/Eigenkapital-Verhältnis	159.6%

Wie hat sich AVCT auf lange Sicht entwickelt?

Historische Performance und Vergleiche

AVCT Aktienübersicht

Belohnungen

Risikoanalyse

Avacta Group Plc Wettbewerber

AIM:BVXP

UK£206.2m

LSE:OXB

UK£389.8m

AIM:AREC

UK£25.5m

AIM:TRX

UK£40.2m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Avacta Group plc Reports Updated Phase 1 Data of Ava6000 At the European Society for Medical Oncology Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors

Avacta Group Plc to Report First Half, 2024 Results on Sep 30, 2024

Avacta Group Plc's (LON:AVCT) 29% Share Price Surge Not Quite Adding Up

CFO & Company Secretary exercised options and sold UK£305k worth of stock

Avacta Group plc Announces Board Changes

Improved Revenues Required Before Avacta Group Plc (LON:AVCT) Shares Find Their Feet

Recent updates

Avacta Group plc Reports Updated Phase 1 Data of Ava6000 At the European Society for Medical Oncology Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors

Avacta Group Plc to Report First Half, 2024 Results on Sep 30, 2024

Avacta Group Plc's (LON:AVCT) 29% Share Price Surge Not Quite Adding Up

CFO & Company Secretary exercised options and sold UK£305k worth of stock

Avacta Group plc Announces Board Changes

Improved Revenues Required Before Avacta Group Plc (LON:AVCT) Shares Find Their Feet

Avacta Group plc Announces Board Changes

Avacta Group Plc, Annual General Meeting, Jun 26, 2024

Avacta Group plc Announces Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta's Ava6000 Phase 1 Trial

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Chief Executive Officer Changes

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Financial data availability

Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting

Avacta Group Plc Announces Update on AVA6000 Phase 1a Clinical Trial Progress

Avacta Group Plc has completed a Follow-on Equity Offering in the amount of £5.448474 million.

Avacta Group Plc has filed a Follow-on Equity Offering in the amount of AUD 20.560243 million.

Investors Give Avacta Group Plc (LON:AVCT) Shares A 26% Hiding

Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer

Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division

Price target decreased by 13% to UK£1.38

Avacta Group plc Provides Detailed Pre-Clinical, Clinical and Pharmacokinetic Data from the Phase 1A Dose Escalation Study

First half 2023 earnings released: UK£0.043 loss per share (vs UK£0.036 loss in 1H 2022)

New major risk - Financial position

Avacta Group Plc Announces Management Changes

Avacta Group plc Announces Successful Completion of ALS-6000-101 Sixth Dose Escalation

Avacta Group Plc to Report First Half, 2023 Results on Sep 28, 2023

New minor risk - Share price stability

Getting In Cheap On Avacta Group Plc (LON:AVCT) Is Unlikely

Avacta Announces Successful Completion of Fifth Dose Escalation in Ava6000 Phase 1 Clinical Study

Would Avacta Group (LON:AVCT) Be Better Off With Less Debt?

Avacta Group plc Appoints Shaun Chilton to the Board as Non-Executive Director

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Avacta Group Plc, Annual General Meeting, Jun 28, 2023

Avacta Group plc acquired Coris Bioconcept SRL for £10.4 million.

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Avacta Group plc Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

Price target decreased to UK£1.55

High number of new and inexperienced directors

Price target decreased to UK£1.55

Avacta Group Plc (AIM:AVCT) conditionally agreed to acquire Launch Diagnostics Holdings Limited for £37 million.

First half 2022 earnings released: UK£0.036 loss per share (vs UK£0.041 loss in 1H 2021)

Avacta Group Plc to Report First Half, 2022 Results on Sep 29, 2022

Avacta Group plc Announces Phase I Study of AVA6000 Advances to Fourth Cohort

High number of new and inexperienced directors

Avacta Group Plc announced that it has received funding

Avacta Group Plc Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group Plc, Annual General Meeting, Jun 23, 2022

Avacta Group Plc Relocates its Therapeutics Division to New Headquarters at Scale Space, in Imperial College's White City Campus, London

Less than half of directors are independent

Full year 2021 earnings released: UK£0.11 loss per share (vs UK£0.084 loss in FY 2020)

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group plc Selects Second Pre|Cision™ Pro-Drug Candidate for Development

Avacta Group plc Provides Update on AffiDX SARS-CoV-2 Antigen Lateral Flow Test and Detection of the Omicron Variant

Avacta Group Plc Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Has Received A CE Mark for Use as A Consumer Self-Test in the UK and EU

Avacta Group Plc Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant

Avacta Group plc Announces US Food and Drug Administration Approval of IND Application for AVA6000

Erträge & Einnahmen